MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1210/clinem/dgad608

Медицинская библиотека · The Journal of clinical endocrinology and metabolism · 2024

Reassuring Data on the Cardiovascular Risk in Adults With X-linked Hypophosphatemia Receiving Conventional Therapy.

Bouzemane Alexandre, Vignot Emmanuelle, Derain Dubourg Laurence, De Mul Aurélie, Molin Arnaud, Chapurlat Roland, Fontanges Elisabeth, Delsart Daphne, Akbari Alireza, Huang Shih Han Susan, McIntyre Christopher W, Bacchetta Justine, Lemoine Sandrine

Наблюдательное исследованиеСтатьяПеревод в очереди

Аннотация

CONTEXT: X-linked hypophosphatemia (XLH) is a rare genetic disorder that results in increased plasma levels of fibroblast growth factor 23 (FGF23). Several studies have demonstrated a direct association between FGF23 and cardiovascular mortality in cohorts of patients with chronic renal failure. However, in patients with XLH, studies on the cardiovascular impact of the disease are rare, with contradictory results.

OBJECTIVE

The aim was to assess whether the disease led to an increased cardiovascular risk.

METHODS

We conducted a single-center retrospective observational study on a local cohort of adult patients with XLH. The primary endpoint was a composite endpoint of the frequency of left ventricular hypertrophy (LVH) or presence of high blood pressure. Our secondary objectives were to assess echocardiographic, pulse wave velocity, and central blood pressure data as other markers of CV health. Independently of this cohort, tissue sodium content with magnetic resonance imaging was studied in 2 patients with XLH before and after burosumab.

RESULTS

Twenty-two patients were included. Median serum phosphate was 0.57 (0.47-0.72) mmol/L and FGF23 94 pg/L (58-2226). Median blood pressure was 124 (115-130)/68 (65-80) mm Hg, with only 9% of patients being hypertensive. A majority of patients (69%) had no LVH, only 1 had a left ventricular mass >100 g/m² and 25% of patients had left ventricular remodeling. Pulse wave velocity was normal in all patients. No differences in skin and muscle sodium content were observed before and after burosumab in the 2 patients who underwent sodium magnetic resonance imaging.

CONCLUSION

We found no elevated risk of developing hypertension or LVH in patients with XLH.

Для цитирования: Bouzemane Alexandre, Vignot Emmanuelle, Derain Dubourg Laurence, De Mul Aurélie, Molin Arnaud, Chapurlat Roland, Fontanges Elisabeth, Delsart Daphne, Akbari Alireza, Huang Shih Han Susan, McIntyre Christopher W, Bacchetta Justine, Lemoine Sandrine. Reassuring Data on the Cardiovascular Risk in Adults With X-linked Hypophosphatemia Receiving Conventional Therapy.. The Journal of clinical endocrinology and metabolism. 2024. DOI: 10.1210/clinem/dgad608.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.